Cargando…
Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas
Artemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral treatment for children with severe febrile illnesses in malaria-endemic areas. The target profile required that such product should be cheap, easy to administer by non-medically qualified persons, rapi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier/North-Holland Biomedical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045394/ https://www.ncbi.nlm.nih.gov/pubmed/24726300 http://dx.doi.org/10.1016/j.ijpharm.2014.04.023 |
_version_ | 1782319313585176576 |
---|---|
author | Gaubert, Alexandra Kauss, Tina Marchivie, Mathieu Ba, Boubakar B. Lembege, Martine Fawaz, Fawaz Boiron, Jean-Michel Lafarge, Xavier Lindegardh, Niklas Fabre, Jean-Louis White, Nicholas J. Olliaro, Piero L. Millet, Pascal Gaudin, Karen |
author_facet | Gaubert, Alexandra Kauss, Tina Marchivie, Mathieu Ba, Boubakar B. Lembege, Martine Fawaz, Fawaz Boiron, Jean-Michel Lafarge, Xavier Lindegardh, Niklas Fabre, Jean-Louis White, Nicholas J. Olliaro, Piero L. Millet, Pascal Gaudin, Karen |
author_sort | Gaubert, Alexandra |
collection | PubMed |
description | Artemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral treatment for children with severe febrile illnesses in malaria-endemic areas. The target profile required that such product should be cheap, easy to administer by non-medically qualified persons, rapidly effective against both malaria and bacterial infections. Analytical and pharmacotechnical development, followed by in vitro and in vivo evaluation, were conducted for various AMAZ coformulations. Of the formulations tested, stability was highest for dry solid forms and bioavailability for hard gelatin capsules; AM release from AMAZ rectodispersible tablet was suboptimal due to a modification of its micro-crystalline structure. |
format | Online Article Text |
id | pubmed-4045394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elsevier/North-Holland Biomedical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40453942014-07-01 Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas Gaubert, Alexandra Kauss, Tina Marchivie, Mathieu Ba, Boubakar B. Lembege, Martine Fawaz, Fawaz Boiron, Jean-Michel Lafarge, Xavier Lindegardh, Niklas Fabre, Jean-Louis White, Nicholas J. Olliaro, Piero L. Millet, Pascal Gaudin, Karen Int J Pharm Article Artemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral treatment for children with severe febrile illnesses in malaria-endemic areas. The target profile required that such product should be cheap, easy to administer by non-medically qualified persons, rapidly effective against both malaria and bacterial infections. Analytical and pharmacotechnical development, followed by in vitro and in vivo evaluation, were conducted for various AMAZ coformulations. Of the formulations tested, stability was highest for dry solid forms and bioavailability for hard gelatin capsules; AM release from AMAZ rectodispersible tablet was suboptimal due to a modification of its micro-crystalline structure. Elsevier/North-Holland Biomedical Press 2014-07-01 /pmc/articles/PMC4045394/ /pubmed/24726300 http://dx.doi.org/10.1016/j.ijpharm.2014.04.023 Text en © 2014 The Authors http://creativecommons.org/licenses/by/3.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Gaubert, Alexandra Kauss, Tina Marchivie, Mathieu Ba, Boubakar B. Lembege, Martine Fawaz, Fawaz Boiron, Jean-Michel Lafarge, Xavier Lindegardh, Niklas Fabre, Jean-Louis White, Nicholas J. Olliaro, Piero L. Millet, Pascal Gaudin, Karen Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas |
title | Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas |
title_full | Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas |
title_fullStr | Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas |
title_full_unstemmed | Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas |
title_short | Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas |
title_sort | preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045394/ https://www.ncbi.nlm.nih.gov/pubmed/24726300 http://dx.doi.org/10.1016/j.ijpharm.2014.04.023 |
work_keys_str_mv | AT gaubertalexandra preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT kausstina preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT marchiviemathieu preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT baboubakarb preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT lembegemartine preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT fawazfawaz preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT boironjeanmichel preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT lafargexavier preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT lindegardhniklas preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT fabrejeanlouis preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT whitenicholasj preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT olliaropierol preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT milletpascal preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas AT gaudinkaren preliminarypharmaceuticaldevelopmentofantimalarialantibioticcotherapyasaprereferralpaediatrictreatmentoffeverinmalariaendemicareas |